ASSEMBLY BIOSCIENCES, INC.

ASMB · Nasdaq · SIC 2834: Pharmaceutical Preparations
306
SEC Filings

Business Summary

Overview We are a biotechnology company developing innovative therapeutics targeting serious viral diseases with the potential to improve the lives of patients worldwide. Our pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPIs) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus (HDV) entry inhibitor; and (3) a highly potent next-generation capsid assembly modulator (CAM)...

Next Earnings

Q2 FY2026 — expected 2026-08-10

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionASMBdiscussed_in_filing Cybersecurity
topic_mentionASMBdiscussed_in_filing Cybersecurity
topic_mentionASMBdiscussed_in_filing Healthcare & Bio
topic_mentionASMBdiscussed_in_filing Healthcare & Bio

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-192025-12-310001193125-26-115992EDGAR68K words
2025-03-202024-12-310000950170-25-042673EDGAR—
2024-03-282023-12-310000950170-24-038057EDGAR—
2023-03-222022-12-310000950170-23-009184EDGAR—
2022-03-112021-12-310001564590-22-009855EDGAR—
2021-02-252020-12-310001564590-21-008878EDGAR—
2020-03-042019-12-310001564590-20-008696EDGAR—
2019-02-282018-12-310001144204-19-011361EDGAR—
2018-03-082017-12-310001144204-18-013474EDGAR—
2017-03-022016-12-310001144204-17-012234EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-102025-09-300001193125-25-274277EDGAR34K words
2025-08-062025-06-300000950170-25-104060EDGAR—
2025-05-082025-03-310000950170-25-066991EDGAR—
2024-11-072024-09-300000950170-24-123402EDGAR—
2024-08-082024-06-300000950170-24-093998EDGAR—
2024-05-082024-03-310000950170-24-055680EDGAR—
2023-11-082023-09-300000950170-23-061134EDGAR—
2023-08-092023-06-300000950170-23-040626EDGAR—
2023-05-042023-03-310000950170-23-017931EDGAR—
2022-11-082022-09-300000950170-22-023233EDGAR—
2022-08-092022-06-300001564590-22-028763EDGAR—
2022-05-122022-03-310001564590-22-019879EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-300001193125-26-131872EDGAR1K words
2026-03-190001193125-26-115980EDGAR—
2025-12-080001193125-25-311251EDGAR—
2025-11-100001193125-25-274235EDGAR—
2025-08-110001193125-25-178092EDGAR—
2025-08-080001193125-25-176138EDGAR—
2025-08-060000950170-25-104020EDGAR—
2025-06-250000950170-25-089949EDGAR—
2025-06-090000950170-25-083830EDGAR—
2025-05-080000950170-25-066946EDGAR—

306 total filings indexed. 274 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Company Identity

CIK0001426800
TickerASMB
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: c707b734b17c6245631b1423f65cc3ef43aa7a6c3b38e70d712290c320f2519f
parent: 5bb67ce49519d3cbf6bfcdb739a47224dd734592b021c437d35e87ebbd888f15
content hash: e7736341f9118ac72371dba1ab9694c3dc7f1e4cd0cda3306d4412512eac4fb2
signed: 2026-04-13T04:43:45.331Z
sources: 22 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf